Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
RET Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2024
RET Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2024
RET is an abbreviation for "rearranged during transfection", as the DNA sequence of this gene was originally found to be rearranged within a 3T3 fibroblast cell line following its transfection with DNA taken from human lymphoma cells. The human gene RET is localized to chromosome 10 and contains 21 exons. The RET proto-oncogene encodes a receptor tyrosine kinase; RET loss of function mutations are associated with the development of Hirschsprung's disease. while gain of function mutations are associated with the development of various types of human cancer, including medullary thyroid carcinoma, multiple endocrine neoplasia type 2A and 2B, pheochromocytoma, and parathyroid hyperplasia.
Mechanism of action (MOA) of RET Inhibitor is RET inhibitors are targeted therapies that act on tumors with activating alterations in the RET proto-oncogene, such as point mutations or fusions. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of cancer cells. RET Inhibitor is used in the treatment of lymphoma, leukemia, sarcoma, carcinoma, endocrine system disorder, glioblastoma, bronchial neoplasm, digestive system neoplasm, immunoproliferative disorders, hematologic disorders, breast diseases, genital diseases, etc. Increased prevalence of autoimmune disorders and various cancers are the key drivers for the RET Inhibitor market. For instance, according to the World Cancer Research Fund International 2020, there were an estimated 18.1 million cancer cases around the world in 2020; of these, 9.3 million cases were in men and 8.8 million in women. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in RET inhibitors. For instance, Merck’s Keytruda (Pembrolizumab) was launched for the treatment of endometrial carcinoma. Moreover, to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instance, Takeda’s Motesanib (AMG 706) for the indication of non-small cell lung cancer is under the various stages of clinical studies.
Key Market Developments:
Approved Drug Molecules and Brand Names for RET Inhibitor:
Drugs under the Pipeline for RET Inhibitor:
Clinical Activity and Developments of RET Inhibitor:
Up until June 2023, there will be about 46 companies with over 35 compounds that focus on various forms of cancer diseases and endocrine diseases. For these molecules, more than 1,337 clinical trials are being conducted and the majority are in phase-2 and phase-3 clinical trials by the players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
Sitravatinib (MGCD516) |
37 |
|
Motesanib (AMG 706) |
25 |
|
HA121-28 |
5 |
|
Agerafenib (RXDX-105) |
3 |
|
AUR-109 |
2 |
A molecule such as Sutent (Sunitinib) was developed by Pfizer for the line of treatment for adjuvant treatment for patients at a high risk of recurrent renal cell carcinoma following nephrectomy and treatment of pancreatic neuroendocrine tumor. Bayer’s Stivarga (Regorafenib) is used for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. Sanofi’s Caprelsa (Vandetanib) for the treatment of thyroid cancer. Eli Lilly’s Retevmo (Selpercatinib) for the treatment of advanced RET-driven lung and thyroid cancers.
Total sales of Merck’s Keytruda (Pembrolizumab) for the full year was US$20,937 million in FY2022 with a 22% increase than FY2021. In the fourth quarter, sales were US$5,450 in FY2022. Global sales growth of Keytruda reflects continued strong momentum from metastatic indications including certain types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, triple-negative breast cancer (TNBC) and microsatellite instability-high (MSI-H) cancers, and increased uptake across recent earlier-stage launches, including certain types of neoadjuvant/adjuvant TNBC in the US Also contributing to growth in oncology was increased alliance revenue from Lynparza, which grew 9% to $292 million, driven primarily by higher demand in the US Increase incidence of cancer population ranging from adenocarcinoma to leukemia and endocrine system diseases in the US also contributing to growth in oncology; Seems to create the opportunity for the future and burgeon the growth of the RET Inhibitor market. For instance, according to American Thyroid Association 2023, around more than 12% of the US population will develop a thyroid condition during their lifetime and estimated 20 million Americans have some form of thyroid disease and is expected to Creates lucrative opportunity for RET Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Sutent (Sunitinib), Focus V (Anlotinib), Stivarga (Regorafenib), Caprelsa (Vandetanib), etc. are the few FDA-approved RET inhibitors.
Total sales of Merck’s Keytruda (Pembrolizumab) for the full year were US$ 20,937 million in FY2022 with a 22% increase than FY2021.
Blueprint Medicines, Eli Lilly, Roche, Exelixis, Sanofi, and Merck are a few leading market players in GM-CSF.
carcinoma, endocrine system disorder, glioblastoma, bronchial neoplasm, digestive system neoplasm, immunoproliferative disorders, etc are the major indications of RET Inhibitor.
There are a total of 22 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.